RT Journal Article
SR Electronic
T1 Towards Internationally standardised humoral Immune Correlates of Protection from SARS-CoV-2 infection and COVID-19 disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.21.21257572
DO 10.1101/2021.05.21.21257572
A1 Castillo-Olivares, Javier
A1 Wells, David A.
A1 Ferrari, Matteo
A1 Chan, Andrew
A1 Smith, Peter
A1 Nadesalingam, Angalee
A1 Paloniemi, Minna
A1 Carnell, George
A1 Ohlendorf, Luis
A1 Cantoni, Diego
A1 Mayora-Neto, Martin
A1 Palmer, Phil
A1 Tonks, Paul
A1 Temperton, Nigel
A1 Wagner, Ralf
A1 Neckermann, Patrick
A1 Peterhoff, David
A1 Doffinger, Rainer
A1 Kempster, Sarah
A1 Otter, Ashley
A1 Semper, Amanda
A1 Brooks, Tim
A1 Page, Mark
A1 Albecka, Anna
A1 James, Leo C.
A1 Briggs, John
A1 Schwaeble, Wilhelm
A1 Baxendale, Helen
A1 Heeney, Jonathan
YR 2021
UL http://medrxiv.org/content/early/2021/05/23/2021.05.21.21257572.abstract
AB Precision monitoring of antibody responses during the COVID-19 pandemic is increasingly important during large scale vaccine rollout and rise in prevalence of Severe Acute Respiratory Syndrome-related Coronavirus-2 (SARS-CoV-2) variants of concern (VOC). Equally important is defining Correlates of Protection (CoP) for SARS-CoV-2 infection and COVID-19 disease. Data from epidemiological studies and vaccine trials identified virus neutralising antibodies (Nab) and SARS-CoV-2 antigen-specific (notably RBD, and S) binding antibodies as candidate CoP. In this study, we used the World Health Organisation (WHO) international standard to benchmark neutralising antibody responses and a large panel of binding antibody assays to compare convalescent sera obtained from: a) COVID-19 patients; b) SARS-CoV-2 seropositive healthcare workers (HCW) and c) seronegative HCW. The ultimate aim of this study, was to identify biomarkers of humoral immunity that could be used as candidate CoP in internationally accepted unitage. Whenever suitable, the antibody levels of the samples studied were expressed in International Units (INU) for virus neutralisation assays or International Binding Antibody Units (BAU) for ELISA tests. In this work we used commercial and non-commercial antibody binding assays; a lateral flow test for detection of SARS-CoV-2-specific IgG / IgM; a high throughput multiplexed particle flow cytometry assay for SARS-CoV-2 Spike (S), Nucleocapsid (N) and Receptor Binding Domain (RBD) proteins); a multiplex antigen semi-automated immuno-blotting assay measuring IgM, IgA and IgG; a pseudotyped microneutralisation test (pMN) and electroporation-dependent neutralisation assay (EDNA). Our results indicate that overall, severe COVID-19 patients showed statistically significantly higher levels of SARS-CoV-2-specific neutralising antibodies (average 1029 IU/ml) than those observed in seropositive HCW with mild or asymptomatic infections (379 IU/ml) and that clinical severity scoring, based on WHO guidelines was tightly correlated with neutralisation and RBD / S binding assays. In addition, there was a positive correlation between severity, N-antibody assays and intracellular virus neutralisation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was undertaken by the Humoral Immune Correlates to COVID-19 (HICC) consortium, funded by the UKRI and NIHR; grant number G107217 (COV0170 - HICC: Humoral Immune Correlates for COVID-19). RW and SE received funding from the StMWK (ForCOVID, Bavaria, Germany)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approved by Research Ethics Committee Wales, IRAS: 96194 12/WA/0148. Amendment 5All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available referred to in the manuscript is available on request